Isolation and identification of actinomycetes strains from Switzerland and their biotechnological potential by Arn, Fabienne et al.
382 CHIMIA 2020, 74, No. 5 Building Bridges Between Biotechnology and chemistry – in memoriam oreste ghisalBa
doi:10.2533/chimia.2020.382  Chimia 74 (2020) 382–390 © F. Arn, D. Frasson, I. Kroslakova, F. Rezzonico, J. F. Pothier, R. Riedl, M. Sievers
*Correspondence: Prof. Dr. M. Sieversb, E-mail: martin.sievers@zhaw.ch
aInstitute of Chemistry and Biotechnology, Organic and Medicinal Chemistry, ZHAW Zurich University of Applied Sciences, Campus Reidbach, CH-8820 Wädenswil, Swit-
zerland; bInstitute of Chemistry and Biotechnology, Microbiology and Molecular Biology, ZHAW, Campus Reidbach; cInstitute of Natural Resource Sciences, Environmen-
tal Genomics and Systems Biology, ZHAW, Campus Reidbach. 
§Equally contributing first authors
Isolation and Identification of 
Actinomycetes Strains from Switzerland 
and their Biotechnological Potential
Fabienne Arna§, David Frassonb§, Ivana Kroslakovab, Fabio Rezzonicoc, Joël F. Pothierc, 
Rainer Riedla, and Martin Sieversb*
Abstract: Actinomycetes strains isolated from different habitats in Switzerland were investigated for production of 
antibacterial and antitumoral compounds. Based on partial 16S rRNA gene sequences, the isolated strains were 
identified to genus level. Streptomyces as the largest genus of Actinobacteria was isolated the most frequently. 
A screening assay using the OmniLog instrument was established to facilitate the detection of active compounds 
from actinomycetes. Extracts prepared from the cultivated strains able to inhibit Staphylococcus aureus and 
Escherichia coli were further analysed by HPLC and MALDI-TOF MS to identify the produced antibiotics. In 
this study, the bioactive compound echinomycin was identified from two isolated Streptomyces strains. Natural 
compounds similar to TPU-0037-C, azalomycin F4a 2-ethylpentyl ester, a derivative of bafilomycin A1, milbe-
mycin-α8 and dihydropicromycin were detected from different isolated Streptomyces strains. Milbemycin-α8 
showed cytotoxic activity against HT-29 colon cancer cells. The rare actinomycete, Micromonospora sp. Stup16_
C148 produced a compound that matches with the antibiotic bottromycin A2. The draft genome sequence from 
Actinokineospora strain B136.1 was determined using Illumina and nanopore-based technologies. The isolated 
strain was not able to produce antibacterial compounds under standard cultivation conditions. The antiSMASH 
bioinformatics analyses of the genome from strain B136.1 identified biosynthetic gene clusters with identity 
values between 4% to 90% to known gene clusters encoding antibiotics. The combinations of cultivation con-
ditions, screening assays, analytical methods and genome mining are important tools to characterize strains of 
actinomycetes for the identification of their potential to produce natural compounds with antimicrobial activity.
Keywords: Actinomycetes · Antibacterial compounds · AntiSMASH · Cultivation · Drug discovery
Introduction
The development of antibiotic resistance is a major global 
threat for public health. The past decades have seen a dramatic 
increase in bacteria that are resistant to one or multiple antibiotics. 
Unfortunately, the industry pipelines for novel antibiotics have 
run dry. Therefore, there is tremendous need for the generation 
of new strategies to fight infections caused by resistant bacterial 
pathogens.[1] Besides the design and synthesis approach toward 
novel antibiotics, microbial extract screening has been and will 
be a valuable source of extraordinary molecules with antibiotic 
activity.[2]
Actinomycetes are a diverse group of Gram-positive bacteria, 
which are able to form spores and are characterized by a filamen-
tous and branching growth pattern. Spore germination results in a 
vegetative growth pattern of actinomycetes forming substrate my-
celium.[3] The transition from vegetative growth to the formation 
of reproductive aerial hyphae is the response of the cells to nutrient 
depletion. A proportion of the vegetative mycelium lyses to sup-
port the remaining cells with nutrition. An increased production of 
secondary metabolites is observed during this development stage. 
The antibiotics produced during this development stage inhibit 
other microorganisms competing for the same nutrition.[4] Spore 
formation, pigment production and antibiotic production are reg-
ulated by quorum sensing. The autoinducer γ-butyrolactone sys-
tem seems to be limited to the phylum Actinobacteria and plays 
important roles as signalling molecule.[5] Most of the currently 
used antibiotics derive from actinomycetes with Streptomyces be-
ing the main producer. One of the first antibiotics discovered was 
streptomycin obtained from Streptomyces griseus which has been 
isolated from the farm soil of the Rutgers Agriculture School and 
was used to treat tuberculosis. For this work, Selman Waksman 
received the Nobel Prize in 1952.[6] To honour the contribution of 
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ed in 100 ml sterile deionized water for 30 mins under shaking 
conditions at 28 °C. Serial dilutions of the supernatants of the 
obtained homogenates were plated on different agar media. One 
medium used for cultivation of isolates from environmental sam-
ples was GYM4, composed of 4 g each of glucose, yeast extract 
and malt extract per litre of demineralized water.[10] In addition, 
media from the International Streptomyces Project described by 
Shirling and Gottlieb[11] and ZSSE agar containing starch and 
soil extract[12] were used. Suspension of 100 mg/L nystatin, 100 
mg/L cycloheximide and 50 mg/L nalidixic acid were added to 
the media after autoclaving to prevent growth of fungi and Gram-
negative bacteria. Inoculated agar plates were incubated at 28 °C 
for up to one month. Obtained colonies were further purified on 
R2A agar (Sigma Aldrich). Pure cultures were obtained by re-
peated streaking on R2A agar. The isolated strains showed dif-
ferent morphological appearance with respect to colony shape 
and size on agar plate and some isolates identified as members 
of the genus Micromonospora were able to produce red pig-
ments. The isolated strains were maintained as glycerol stocks 
in cryocultures at –80 °C. Determination of partial 16S rRNA 
gene sequences and BLASTn analyses classified the investigated 
 actinomycetes strains into three different genera. The 16S rRNA 
gene was amplified from the isolated DNA of the different strains 
using primers 8f (5’- AGA GTT TGA TCC TGG CTC AG -3’) 
and 1392r (5’- ACG GGC GGT GTG TAC A -3’).[13] A 1,384 bp 
fragment spanning from the V1 to part of the V9 region of the 
16S rRNA gene was obtained and compared with available se-
quences in the GenBank/EMBL/DDBJ database using BLASTn 
search, revealing an identity to genus level. The identified genera 
were Streptomyces (7 isolates), Micromonospora (1 isolate) and 
Actinokineospora (1 isolate). 
S. griseus to human healthcare, the bacterium is now officially 
recognised as New Jersey’s State Microbe (The Scientist, May 
13, 2019). Most antibiotics used today were discovered during 
the period 1940–1960, which is referred to as the golden era 
of antibiotic discovery.[7] The antibiotics produced from actin-
omycetes belong to different chemical classes such as amino-
glycosides (streptomycin, gentamycin, neomycin, tobramycin), 
glycopeptides (vancomycin, teicoplanin), macrolides (erythro-
mycin, carbomycin), amphenicols (chloramphenicol), ansam-
ycins (rifamycin), tetracyclines (oxytetracycline, chlortetracy-
cline), lincosamides (clindamycin), lipopeptides (daptomycin), 
β-lactams (cephalosporin), and aminocoumarins (novobiocin). [8] 
Actinomycetes represent a promising source to isolate novel 
antibacterial compounds, which are urgently needed to combat 
antibiotic-resistant bacteria. Improved screening methods led to 
the discovery of the cyclic peptide compound lassomycin from 
Lentzea kentuckyensis which is a Clp protease inhibitor and active 
against drug-resistant strains of Mycobacterium tuberculosis.[9] 
The majority of the compounds with biological activities pro-
duced from actinomycetes is still undiscovered. In the present 
study, Streptomyces and rare actinomycetes strains isolated in 
Switzerland were investigated for their antibacterial and cytotox-
ic activities. 
Isolation and Identification of Strains of Actinobacteria 
from Switzerland
Nine strains of actinomycetes collected from different habi-
tats in Switzerland were investigated for antibacterial and cyto-
toxic activities (Table 1). For isolation of actinomycetes strains 
from soil, the collected samples were air dried in an incubator 
at 28 °C for seven days. Then 10 g of dried soil was resuspend-
Table 1. Investigated strains for production of antibacterial and cytotoxic compounds.
Genus Origin Coordinates Inhibition [m/z] Compound
Strain








Streptomyces Moor 47°14'43.0''N 
8°30'26.4''E




Streptomyces Grassland soil 47°13'59.0''N 
8°07'54.6''E




Streptomyces Soil 47°13'05.5''N 
8°40'50.0''E







Streptomyces Forest soil 46°20'41.0''N 
8°00'27.4''E



















Streptomyces Worm castings 47°08'04.1"N 
8°07'56.5"E








aIdentification was based on reference standards
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A combination of dye reduction and visualisation of respiratory 
growth curves provides a reliable and highly informative method 
to determine the antibacterial activity of investigated compounds.
Preparation of Extracts and HPLC Analysis
Culture supernatants from actinomycetes strains, which 
showed inhibition in the cross-streaking experiment, were ex-
tracted with ethyl acetate from culture grown in all three media 
(GYM4, R2A and NL148sb) for 7 days with shaking at 100 rpm 
at 28 °C. The extracts were evaporated to dryness and dissolved 
in methanol. Streptomyces sp. strain sima1_6 showed potential 
antibacterial activity in the preliminary cross-streaking assay, but 
the supernatant of the cultivated strain failed to inhibit both E. 
coli and S. aureus. For isolation of the antibacterial compound 
from strain sima1_6 grown on GYM4 agar, the fragmented myce-
lium and agar was extracted overnight with acetone, concentrated 
on a rotary evaporator and dissolved in methanol. The methanol 
solvents containing the extracts were subjected to HPLC (HPLC 
Series 1200, Agilent Technologies) analysis. The extracts were 
chromatographed through a precolumn (Strategy C18-2) followed 
by the HPLC column (Uptisphere Strategy C18-HQ), both from 
Interchim. The column temperature was 40 °C. Elution was per-
formed using a flow-rate of 1 ml/min. Elution solvent changed 
from 95% water, 4.8% methanol and 0.2% acetic acid (solvent A) 
to 95% methanol, 4.8% water and 0.2% acetic acid (solvent B) 
in 10 mins, followed by additional 8 mins with solvent B. Single 
fractions were collected, concentrated and dissolved in DMSO. 
For example, the extract of isolate Streptomyces sp. strain Stup16_
B49.2 showed two distinct peaks in the HPLC chromatogram. 
The first peak had a retention time of 8.13 min and the second 
peak eluates at 13.24 min (Fig. 1). The main peak (retention time: 
13.24 min) showed antibacterial activity against S. aureus and 
E. coli. In general, all obtained fractions of each individual peak 
from the HPLC separation of the investigated extracts were ana-
lysed for inhibitory activity by measuring growth kinetics using 
the OmniLog instrument.
Identification of the Extracted Compounds
The active compounds from seven strains of Streptomyces 
species, named Stup16_B49.2, sima1_6, Stup16_B146, OPOK_
MB_B11, Stup18_J70, OPOK_MB_A9, W367A and one strain of 
Micromonospora sp. Stup16_C148, were characterised chemical-
ly. HPLC-purified organic fractions of these strains showing anti-
bacterial properties were subjected to MALDI-TOF MS measure-
ment for molecular mass determination followed by MALDI-TOF 
MS/MS to obtain their fragmentation pattern. Mass spectrometric 
data were acquired using an Autoflex Speed (Bruker Daltonics) 
equipped with a 355 nm Nd:YAG laser. During the measurement, 
the instrument was operating in reflectron mode with positive po-
larity. The matrix used was 2,5-dihydroxybenzoic acid dissolved 
in pure methanol at concentration of 15 mg/ml. HPLC purified 
fractions were also dissolved in methanol and mixed with matrix 
solution. To facilitate the ion formation the sample-matrix mix-
ture was spiked with a solution of NaCl saturated in pure ethanol. 
Identical measuring conditions were applied to obtain the spectra 
of reference standards and isolated HPLC compounds. The soft-
ware mMass (open source mass spectrometry tool) version 5.5.0 
was used to create mass spectra plots from measured raw data.
Based on the measured mass the most similar compound 
was identified by comparison with following databases: Reaxys, 
StreptomeDB, NPEdia, SuperNaturalDatabase and the Natural 
Product Atlas. StreptomeDB for example contains more than 
2,400 different secondary metabolites produced from more than 
1,900 strains of Streptomyces.[15] MS/MS fragmentation patterns 
were generated from commercially available standards and from 
the isolated compounds. The peak patterns of the acquired spec-
tra were compared to determine whether the spectrum of the in-
Primary Screening of the Isolated Strains for 
Antibacterial Activities
The isolated actinomycetes strains were tested for their abil-
ity to produce antibacterial compounds against Staphylococcus 
aureus ATCC 25923 and Escherichia coli TOP10F' (Thermo 
Fisher Scientific) using the cross-streak method. This preliminary 
screening is a simple and rapid method to investigate strains for 
production of antimicrobial metabolites. Three different media, 
R2A, GYM4 and NL148sb, were used for the cross-streaking ex-
periment. NL148sb was described recently by Lütz and cowork-
ers.[14] An isolated strain of Actinobacteria was cross-streaked as 
a single central line vertical on each of the three agar plates and 
incubated for 5 to 7 days at 28 °C until growth occurred. E. coli 
and S. aureus as test strains were each cross-streaked horizontally 
as two separate lines left and right from the original streak of the 
Actinobacteria strain. The plates were incubated for 24 h at 37 °C 
to determine the growth of the tested strains. Antagonism is ob-
served by the inhibition of growth of selected pathogenic bacteria 
used as test strains. Inhibition zones were estimated qualitatively, 
whereby a strong inhibition was indicated by growth inhibition 
of the line of the tested strain at least by two-third of its length. 
Weak inhibition was indicated by attenuated growth of the test 
strain close to the area of the actinomycetes strain used in the 
assay. Of nine strains of actinomycetes tested for antibacterial and 
antitumoral compound production, seven strains showed strong 
inhibition against S. aureus and weak to no inhibition against E. 
coli in the preliminary screening, and one strain was not able to 
inhibit the two test strains using the three different media in the 
cross-streaking method. One strain showed cytotoxic activity 
against the human colon cancer cell line HT-29.
The following seven strains which showed antibacterial activ-
ity using the cross-streaking method are: Streptomyces sp. strain 
Stup16_B146, Streptomyces sp. strain Stup16_B49.2 (the two 
strains were isolated from different grassland soils), Streptomyces 
sp. strain OPOK_MB_B11 (isolated from soil), Streptomyces sp. 
strain sima 1_6 (isolated from moor), Streptomyces sp. strain 
Stup18_J70 (isolated from forest soil), Streptomyces sp. strain 
W367A (isolated from worm castings) and Micromonospora sp. 
strain Stup16_C148 (isolated from soil of a riverbank). These sev-
en isolates, which showed antibacterial activity, were selected for 
further analysis to identify the antibacterial compounds. 
Secondary Screening of Compounds for Antibacterial 
Activities Using the OmniLog Instrument
A colorimetric assay in combination with respiratory growth 
curves was applied to optimise the screening method for deter-
mination of antibacterial activities from extracted compounds. 
The OmniLog instrument (Biolog) was used to measure growth 
inhibition of E. coli TOP 10F' and S. aureus ATCC 25923. For 
direct visualisation of inhibition, microtiter plate wells were in-
oculated with 103 bacterial cells/ml of each strain in TSB broth 
and incubated in the presence of the compound. The compound 
to be investigated for inhibition was dissolved in DMSO, either in 
form of the extract generated from the supernatant or mycelium of 
the cultivated strain, or as fraction obtained from HPLC. The used 
dyes were Biolog Redox Dye Mix A for E. coli and Biolog Redox 
Dye Mix H for S. aureus. Chloramphenicol (37 µM) and kanamy-
cin (58 µM) were used as positive controls and DMSO 5.3% (v/v) 
as negative control. Kinetics of bacterial growth and dye reduction 
were monitored with a camera of the OmniLog instrument contin-
uously over the course of the experiment up to 24 h. Inhibition of 
bacterial growth does not change the colour of the included dye 
and no visible metabolic activity of the included strains (E. coli or 
S. aureus) is thus detected. Reduction of the dyes indicates growth 
of the test strains used in the assay. By comparing both the colour 
of the used dye and kinetic growth curves within each well, the 
antibacterial effect of the investigated compound was measured. 
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(m/z at 85, 113, 156, 240 and 478). Following the identification 
scheme proposed by Schymanski et al.[16] this result can be clas-
sified with confidence level 3, which means tentative identifica-
tion of a structure, where multiple structures are possible (e.g. 
positional isomers). Further structure elucidation of this com-
pound is therefore needed. A natural compound produced from 
Streptomyces sp. strain OPOK_MB_B11 has m/z of 1202.751 
detected as sodiated ion and is proposed as azalomycin F
4a
 2-eth-
ylpentyl ester. However, a comparison of the fragmentation 
patterns is not possible since the substance is not commercial-
ly available. Streptomyces sp. strain W367A, isolated from the 
Cantone of Lucerne, produced a compound which was detected 
as sodiated ion at m/z of 550.343. Comparing this mass with the 
StreptomeDB database, dihydropicromycin was identified as the 
most similar compound. One rare actinomycete strain, isolated 
from the soil of the riverbank of the Limmat in Unterengstringen, 
Canton of Zurich, was identified as Micromonospora and was 
able to inhibit S. aureus in the secondary screening. The com-
pound of the isolated strain Micromonospora sp. Stup16_C148 
has mass-to-charge ratio m/z of 823.440 when detected as pro-
tonated ion. This matches with bottromycin A2, which has a 
monoisotopic neutral mass of 822.441 determined with high res-
olution electron impact mass spectrometry.[17] Streptomyces sp. 
Stup18_J70 was isolated from forest soil of the Canton of Valais 
and showed strong inhibition of S. aureus in the screening assays. 
The isolated compound has a molecular weight of 787.449 and 
the obtained mass spectrum using MALDI-TOF MS is identical 
to a bafilomycin A1 derivative, which is described in the docu-
ment CN104817547 (B) (patent in Chinese). The structures of the 
compounds from the investigated actinomycetes strains isolated 
in Switzerland are shown in Fig. 4.
Streptomyces Strain Showing Cytotoxic Activity
The in vitro cytotoxic activity of the Streptomyces sp. strain 
OPOK_MB_A9 was investigated using the human colon cancer 
HT- 29 cell line (DSMZ no.: ACC 299). The viability of the cells 
was measured using the MTT assay to estimate cell growth inhibi-
tion in the presence of the active compound of the HPLC fraction 
dissolved in DMSO. HT-29 cells were cultured in RPMI 1640 me-
dium supplemented with 10% (v/v) fetal bovine serum, and 2 mM 
L-glutamine and seeded into 96-well microtiter plates at a con-
centration of 104 cells per well. Viable cells were able to convert 
the yellow MTT (tetrazolium salt) to purple-coloured formazan. 
The produced crystalline formazan was solubilised with DMSO 
after medium removal and a washing step with phosphate buffer 
saline. Optical densities (OD) were measured at 570 nm to de-
vestigated compound matches with the spectrum of the reference 
substance. Using this approach, we identified the antibiotic echi-
nomycin from Streptomyces strains Stup16_B49.2 and sima 1_6. 
Echinomycin was detected as sodiated ion at m/z of 1123.403. 
The fragmentation patterns of echinomycin used as reference sub-
stance (CAS: 512-64-1, Sigma Aldrich) and the active substance 
isolated from Streptomyces strains Stup16_B49.2 generated with 
MALDI-TOF/TOF are shown in Fig. 2. The fragmentation pat-
terns in the mass spectra of the isolated compound and the refer-
ence substance are identical. 
The compound produced from Streptomyces strain Stup16_
B146 was able to inhibit S. aureus in the secondary screening 
using the OmniLog assay. The mass spectrometric analysis of this 
compound resulted in a mass-to-charge ratio m/z peak at 825.522. 
Comparing this mass with the NPEdia database TPU-0037-C 
(CAS: 485815-61-0, AdipoGen Life Sciences) was evaluated 
as a possible candidate for the reference standard. Although MS 
spectra of Stup16_B146 and TPU-0037-C were identical in terms 
of detected m/z and isotopic pattern, the MS/MS fragmentation 
measurement did not result in superimposable spectra as shown 
in Fig. 3. The most intensive peaks of both spectra appeared at 
identical m/z (70, 156, 227, 296 and 380), however several peaks 
were either only present in Stup16_B146 (m/z at 310, 394, 694) 
or had different relative intensity in comparison with TPU-0037-C 
Fig. 1. HPLC chromatogram  
with isolated fractions of an ethyl 
acetate extract from Streptomy-
ces sp. Stup16_B_49.2 grown in 
NL148sb medium. The main peak 
with a retention time of 13.24 min 
corresponds to echinomycin.
Fig. 2. MALDI-TOF MS/MS spectrum of the antimicrobial compound 
produced by Streptomyces sp. Stup16_B49.2 (red spectrum) is identical 
with the spectrum of reference substance echinomycin (blue spectrum). 
The molecular ion of echinomycin can be seen in the spectrum at m/z 
1123.403, which corresponds to the sodiated ion of the molecule.
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termine the cytotoxicity effect of the fraction from Streptomyces 
sp. strain OPOK_MB_A9 on HT-29 cells. DMSO (1% v/v) and 
ionomycin (1% v/v) were used as negative and positive control 
in the assay. The inhibition of the growth of HT-29 cells in the 
wells of the MTT assay was calculated according to the following 
equation:











 is the absorbance of the compound in the HPLC 
fraction, Abs
blank
 is the absorbance of the medium in the well with-
out HT-29 cells to measure the background and Abs
control
 is the 
absorbance of the control reaction, which contained all reagents 
except the compound.
The fraction of Streptomyces sp. strain OPOK_MB_A9 ex-
hibited a strong cytotoxic activity towards HT-29 cells causing 
about 75.8% inhibition after 24 h of incubation. DMSO showed 
no effect on the viability of the HT-29 cells and ionomycin caused 
77.3% inhibition of the used human colon cancer cell line during 
the incubation time of 24 h. Other extracts from actinomycetes 
strains tested were not able to reduce the viability of HT-29 cells. 
Ionomycin used as positive control in the MTT assay showed the 
same inhibitory effect on HT-29 cells as the tested fraction from 
Streptomyces sp. strain OPOK_MB_A9. The mass spectrum de-
termined with MALDI-TOF MS confirmed that the molecular 
weight of the compound causing cytotoxic activity was 701.444 
as a protonated ion. The obtained mass was compared with the 
used databases and matches with a macrolide antibiotic similar 
to milbemycin-α8.
Genome Sequence Data from Actinokineospora Strain
To assess the full potential of secondary metabolite production 
of investigated strains, genome mining is a valuable approach to 
identify biosynthetic gene clusters and to predict the bioactive 
compounds encoded from these groups of genes.
The genus Actinokineospora comprises spore-forming 
members, which form a most distant cluster in the suborder 
Pseudonocardineae.[27] From the strain B136.1, isolated from 
grassland soil in the Canton of Lucerne, a partial 16S rRNA gene 
sequence of 1,295 bp amplified with PCR was determined and 
the BLASTn search indicate that the isolate belongs to the genus 
Actinokineospora. The 16S rRNA gene sequence of the strain has 
been deposited in the European Nucleotide Archive (ENA) and 
received LR740774 as accession number (study PRJEB35546). 
The draft genome sequence from Actinokineospora strain B136.1 
was determined using 150 bp paired-end Illumina MiSeq and 
nanopore-based genome sequencing. For genomic sequencing, 
the total DNA was prepared from 50 ml of strain B136.1 culture 
Fig. 3. MALDI-TOF MS/MS spectrum of the antimicrobial compound 
produced by Streptomyces sp. Stup16_B146 (red spectrum) and refe-
rence substance TPU-0037-C (blue spectrum). 
Fig. 4. Structures of the identi-
fied antibiotic compounds from 
isolated actinomycetes strains in 
Switzerland, namely azalomycin 
F4a 2-ethylpentyl ester,
[18,19] TPU-
0037-C,[20,21] bottromycin A2,[22] 
echinomycin,[23] milbemycin-α8,[24] 
dihydropicromycin.[25] The struc-
ture of bafilomycin A1 is shown in 
the publication of Yu et al.[26] and 
a proposed derivative of the com-
pound is published in the patent 
CN104817547 (B).
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Actinobacteria have already been screened for antibiotic produc-
tion using traditional screening procedures leading to the identi-
fication of known and new antibacterial compounds. The large 
diversity of actinomycetes strains in the environment represents 
a unique source for detection and isolation of natural compounds 
with antibacterial activities. In this work, we have focused on 
the isolation of actinomycetes strains from Switzerland and the 
identification of antibiotics produced by the investigated strains. 
Different types of sampling sites were selected to increase the 
biodiversity of isolated strains.
Echinomycin and TPU-0037-C are available as reference 
standards allowing the generation and comparison of fragmenta-
tion patterns in MALDI TOF/TOF mass spectrometry. Compounds 
similar to azalomycin F
4a
 2-ethylpentyl ester, milbemycin-α8, a 
derivative of bafilomycin A1, dihydropicromycin and bottromy-
cin A2 have been detected from different Streptomyces strains and 
one Micromonospora isolate based on their mass spectra.
Echinomycin is active against clinical isolates of S. aureus and 
is more potent in comparison to vancomycin.[34] Echinomycin be-
longs to the quinomycin class peptide antibiotics containing two 
quinoxaline-2-carbonyl chromophores important for interaction 
with DNA. QXC (quinoxaline-2-carboxylic acid) is the aromatic 
precursor of echinomycin and is produced from the amino acid 
l-tryptophan. At the beginning of the QXC biosynthesis, l-tryp-
tophan is loaded with the help of a small MbtH-like protein onto 
a non-ribosomal peptide synthetase which has both adenylation 
and peptidyl carrier protein domains. The genes responsible for 
the biosynthesis of QXC have been detected in Streptomyces gri-
seovariabilis subsp. bandungensis showing homology to the echi-
nomycin (ecm) and triostin A (trs) gene clusters from S. lasalien-
sis and S. triostinicus, respectively.[35] Echinomycin is not a rare 
antibiotic and was repeatedly detected in this study using HPLC 
and MALDI-TOF/TOF analysis. Combining genome mining in 
identifying genes involved in secondary metabolite production 
and chemical biology using analytical assays will help to identify 
natural compounds, especially in cases where a standard for com-
parison of the detected compound is not available.
Compounds related to TPU-0037-C and azalomycin F
4a
 
2-ethylpentyl ester have been detected in this study from two 
Streptomyces isolates. TPU-0037-C produced from Streptomyces 
platensis strain TP-A0598 is a structural analogue to lydicamycin 
and has been shown to inhibit different Gram-positive bacteria in-
cluding methicillin-resistant S. aureus but failed to inhibit Gram-
negative bacteria like E. coli.[20] Azalomycin F4a 2-ethylpentyl es-
ter is a new macrocyclic lactone produced from a Streptomyces sp. 
strain 211726 isolated from mangrove soil and exhibited antifun-
gal activity against Candida albicans and moderate cytotoxicity 
against human colon cancer cell line HCT-116.[18] Azalomycin F 
showed inhibition against Bacillus subtilis and was not able to in-
hibit E. coli even at higher concentrations.[36] Bottromycin A2 was 
identified from the isolated Micromonospora strain Stup16_C148. 
Bottromycin A2 inhibits bacterial protein synthesis and is active 
against clinical isolated strains of methicillin-resistant S. aureus 
and vancomycin-resistant enterococci.[37] Bottromycin was first 
isolated from the fermentation broth of Streptomyces bottropen-
sis by Waisvisz et al.[38] and the antibiotic is also produced by 
Micromonospora chalcea.[39] The structure of bottromycin A2 is 
unique in nature due to the macrocyclic amidine, rare β‐methyl-
ated amino acids residues and a terminal thiazole. [40] Bottromycin 
A2 is not in clinical use since the antibiotic is unstable in vivo.[37] 
Old antibiotics could undergo a renaissance by modifying them 
chemically to generate more stable and powerful drugs to treat 
diseases caused by pathogenic bacteria.
Most of the antibiotics used today originated from actinomy-
cetes with Streptomyces being the main producer. For example, 
daunorubicin and doxorubicin produced by Streptomyces peuce-
tius are two anthracycline antibiotics and both are used in human 
grown in NL148sb medium at 28 °C on a rotary shaker at 120 
rpm for several weeks up to one month. Cells were harvested, 
resuspended in 8 ml of 10 mM Tris HCl pH 8.0, 1 mM EDTA 
and treated with 100 µg/ml RNAse A (DNAse free) and 40 mg/
ml lysozyme at 55°C for 30 min. Two proteinase K incubation 
steps were performed. First, 8 ml of 10 mg/ml proteinase K (in 
2% SDS) was added. After 2h of incubation at 55 °C, 100 µL 
proteinase K (20 mg/ml) was pipetted to the extraction procedure 
and the solution was incubated overnight. A phenol-chloroform 
extraction was performed, followed by DNA precipitation using 
ethanol and spectrophotometric quantification.[28]
The output of the hybrid assembly using Unicycler v.0.4.7 was 
242 contigs with a size of about 7.6 Mbp. The complete 16S rDNA 
sequence of 1,506 bp was extracted from the genome and used for 
phylogenetic analysis. A phylogenetic tree was reconstructed to 
determine the taxonomic position and relationship of strain B136.1 
to other species of Actinokineospora and closely related taxa. The 
evolutionary history of the tree was inferred by using the Maximum 
Likelihood method and Tamura-Nei model.[29] The evolutionary 
analyses were conducted in MEGA X.[30] The 16S rDNA sequence 
of strain B136.1 is identical to Actinokineospora sp. strain R19-10 
(NBRC 105648) which was isolated from soil of Rishiri Island, 
Hokkaido, Japan. Based on the phylogenetic tree, both strains 
form a separate lineage of evolutionary divergence (Fig. 5). The 
separate lineage of both strains B136.1 and NBRC 105648 within 
the phylogenetic tree reconstructed indicate that both strains from 
Switzerland and Japan could be a new species within the genus 
Actinokineospora. The genetic relatedness between the two ge-
nomes was predicted using the average nucleotide identity (ANI) 
value based on MUMmer comparisons (ANIm) using pyANI 
v.0.2.4. Genomes of two strains from one species typically share ≥ 
95% ANI values among themselves. The boundary of DNA-DNA 
hybridization value of 70% for species delineation corresponds to 
95% ANI.[31] The calculated ANI values of strain B136.1 ranging 
from 85% to 86% with other species of the genus Actinokineospora 
support the evidence that the strain belongs to a new species.
The obtained genome sequence of Actinokineospora sp. 
B136.1 was analysed with the antiSMASH 3.0 program to deter-
mine the secondary metabolite gene clusters of the strain. More 
than 20 biosynthetic gene clusters including polyketide syn-
thase (PKS-I and PKS-II) and nonribosomal peptide synthetases 
(NRPS) genes responsible for the biosynthetic pathways of the 
secondary metabolites have been detected. Based on the genome 
mining with antiSMASH, at least nine biosynthetic gene clus-
ters were identified in strain B136.1 encoding for antibacterial 
properties. The following gene clusters with high and low iden-
tity values to known clusters encoding secondary metabolites 
with potential antibacterial activities were: actinokineosin (90% 
identity with the most similar known cluster), friulimicin (18% 
identity), malacidin (38% identity), laspartomycin (4% identity), 
abyssomicins M-X (62% identity), indanomycin (26% identity), 
hygromycin B (6% identity), amycomicin (25% identity), pris-
tinamycin (29% identity), respectively. In addition, strain B136.1 
has a biosynthetic gene cluster, which is 20% identical to vicen-
istatin as most similar gene cluster. Vicenistatin, biosynthesised 
by the polyketide pathway, has been shown to possess antitumor-
al activity against human leukaemia and colon adenocarcinoma 
cells.[32] None of the biosynthetic gene clusters identified on the 
genome of Actinokineospora sp. strain B136.1 were expressed 
under the cultivation conditions with the three different media 
(R2A, GYM4, NL148sb) used in the laboratory.
Discussion
The World Health Organisation warns that multidrug-resist-
ant bacteria are currently one of the greatest threats to public 
health and immediate action is urgently needed to increase in-
vestments in the discovery of new medicines.[33] Many strains of 
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produced a compound similar to milbemycin-α8 and was found 
to possess inhibitory properties against colon adenocarcinoma 
cell line HT-29. Milbemycins are macrolide antibiotics and were 
isolated from the mycelium of Streptomyces hygroscopicus sub-
sp. aureolacrimosus obtained from a fermentation broth, which 
showed activity against Acarus and larvae of the insects of the or-
cancer chemotherapy.[41] Actinomycetes are well known for their 
production of natural compounds with different biological activi-
ties, including antitumoral properties. Important compounds used 
in chemotherapy to treat cancer are of microbial origin. Many 
antitumoral compounds produced by actinomycetes have in addi-
tion also antimicrobial activity. Streptomyces sp. OPOK_MB_A9 
Fig. 5. Phylogenetic position of Actinokineospora B136.1 with its closely related taxa based on 16S rRNA sequences. The tree with the highest log 
likelihood (-5946.57) is shown. The percentage of trees out of 1000 replications in which the associated taxa clustered together is shown next to the 
branches when above 50%, and the scale bar represents the percentage of substitutions per site. Initial tree(s) for the heuristic search were obtained 
automatically by applying Neighbor-Joining and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Like-
lihood (MCL) approach, and then selecting the topology with superior log likelihood value. The type strain of the species is highlighted with a bold 
superscript T after the strain information; accession numbers are provided between brackets after the strain information and genome sequenced 
strains are highlighted with a dot after the accession number. Amycolatopsis albispora WP1T was used as outgroup.
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ment actionorhodin (act) gene cluster in S. coelicolor M145. The 
wild type S. coelicolor strain M145 has a blue colour appearance 
based on actinorhodin pigment production. The mutated strain 
M145/pWHU2659 (∆actI-ORF2) showed an orange colour from 
undecylprodigiosin visible after loss of the blue pigment actinor-
hodin.[56] CRISPR/Cas is used to activate silent biosynthetic 
gene clusters, which are not expressed under standard cultiva-
tion conditions, to find new natural products. A novel compound 
was detected by an engineered Streptomyces viridochromogenes 
strain DSM 40736 by insertion of constitutive promoter kasOp* 
constructed by Wang et al.[57] in front of the biosynthetic operon 
SSQG_RS26895-26920 of an uncharacterized PKS type II gene 
cluster. The engineered S. viridochromogenes strain produced a 
brown pigment before sporulation, which is a novel polyketide 
with a dihydrobenzo[α]naphthacenequinone core.[58] Studies to 
activate silent biosynthetic gene clusters in the genome of actin-
omycetes strains with this technique are currently performed in 
our laboratory.
Beside the production of natural drugs, Streptomyces has ad-
ditional properties producing enzymes, which are important bi-
ocatalysts like halogenase, polyhydroxyalkanoate depolymerase, 
cytochrome P450 monooxygenase, methyl transferase and imine 
reductase.[59] The degradation of staurosporine to the less toxic 
aglycon K-252c using Streptomyces mediocidicus ATCC 13279 
has been described by Ghisalba and coworkers.[60] Identifying mi-
crobial strains with interesting and novel properties facilitate their 
use in further innovative applications. Access to high quality bio-
logical resources and associated data is important to foster research 
and application in biotechnology. To support the life science com-
munity with well-characterised strains, Prof. Dr. Oreste Ghisalba 
encouraged deposits of microbial resources for long-term mainte-
nance in open collections in accordance with the Nagoya Protocol 
in order to make them available for research activities in academ-
ia, research institutions and industry. Preservation of interesting 
strains is of great importance to prevent loss of microbial resources 
and to utilise them for further applications in the future.[61] The 
published actinomycetes strains isolated in Switzerland will be 
deposited in the Culture Collection of Switzerland (CCOS). The 
CCOS was established in 2009 as the national culture collection 
of Switzerland based on a national need and initiative of Prof. Dr. 
Oreste Ghisalba. He would certainly enjoy the structural beauty 
and diversity of the natural substances with antibiotic effects to be 
discovered from actinomycetes strains. 
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